PURPOSE: Obesity and its metabolic impairments are discussed as major risk factors for sarcopenia leading to sarcopenic obesity. Cushing's syndrome is known to be associated with obesity and muscle atrophy. We compared Cushing's syndrome with matched obese controls regarding body composition, physical performance, and biochemical markers to test the hypothesis that Cushing's syndrome could be a model for sarcopenic obesity. METHODS: By propensity score matching, 47 controls were selected by body mass index and gender as obese controls. Fat mass and muscle mass were measured by bioelectrical impedance analysis. Muscle function was assessed by chair rising test and hand grip strength. Biochemical markers of glucose and lipid metabolism and inflammation (hsCRP) were measured in peripheral blood. RESULTS: Muscle mass did not differ between Cushing's syndrome and obese controls. However, Cushing's syndrome patients showed significantly greater chair rising time (9.5 s vs. 7.3 s, p = 0.008) and significantly lower hand grip strength (32.1 kg vs. 36.8 kg, p = 0.003). Cushing's syndrome patients with impaired fasting glucose have shown the highest limitations in hand grip strength and chair rising time. CONCLUSIONS: Similar to published data in ageing medicine, Cushing's syndrome patients show loss of muscle function that cannot be explained by loss of muscle mass. Impaired muscle quality due to fat infiltration may be the reason. This is supported by the observation that Cushing's syndrome patients with impaired glucose metabolism show strongest deterioration of muscle function. Research in sarcopenic obesity in elderly is hampered by confounding comorbidities and polypharmacy. As Cushing's syndrome patients are frequently free of comorbidities and as Cushing's syndrome is potentially curable we suggest Cushing's syndrome as a clinical model for further research in sarcopenic obesity.
PURPOSE:Obesity and its metabolic impairments are discussed as major risk factors for sarcopenia leading to sarcopenic obesity. Cushing's syndrome is known to be associated with obesity and muscle atrophy. We compared Cushing's syndrome with matched obese controls regarding body composition, physical performance, and biochemical markers to test the hypothesis that Cushing's syndrome could be a model for sarcopenic obesity. METHODS: By propensity score matching, 47 controls were selected by body mass index and gender as obese controls. Fat mass and muscle mass were measured by bioelectrical impedance analysis. Muscle function was assessed by chair rising test and hand grip strength. Biochemical markers of glucose and lipid metabolism and inflammation (hsCRP) were measured in peripheral blood. RESULTS: Muscle mass did not differ between Cushing's syndrome and obese controls. However, Cushing's syndromepatients showed significantly greater chair rising time (9.5 s vs. 7.3 s, p = 0.008) and significantly lower hand grip strength (32.1 kg vs. 36.8 kg, p = 0.003). Cushing's syndromepatients with impaired fasting glucose have shown the highest limitations in hand grip strength and chair rising time. CONCLUSIONS: Similar to published data in ageing medicine, Cushing's syndromepatients show loss of muscle function that cannot be explained by loss of muscle mass. Impaired muscle quality due to fat infiltration may be the reason. This is supported by the observation that Cushing's syndromepatients with impaired glucose metabolism show strongest deterioration of muscle function. Research in sarcopenic obesity in elderly is hampered by confounding comorbidities and polypharmacy. As Cushing's syndromepatients are frequently free of comorbidities and as Cushing's syndrome is potentially curable we suggest Cushing's syndrome as a clinical model for further research in sarcopenic obesity.
Authors: G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: Jasminka Z Ilich; Owen J Kelly; Julia E Inglis; Lynn B Panton; Gustavo Duque; Michael J Ormsbee Journal: Ageing Res Rev Date: 2014-03-12 Impact factor: 10.895
Authors: Robert Kob; L Cornelius Bollheimer; Thomas Bertsch; Claudia Fellner; Marija Djukic; Cornel C Sieber; Barbara E Fischer Journal: Biogerontology Date: 2014-11-07 Impact factor: 4.277
Authors: T C Friedman; G Mastorakos; T D Newman; N M Mullen; E G Horton; R Costello; N M Papadopoulos; G P Chrousos Journal: Endocr J Date: 1996-12 Impact factor: 2.349
Authors: Andrea Oßwald; Eva Plomer; Christina Dimopoulou; Monika Milian; Rainer Blaser; Katrin Ritzel; Anne Mickisch; Ferengis Knerr; Milan Stanojevic; Klaus Hallfeldt; Jochen Schopohl; Klaus A Kuhn; Günter Stalla; Felix Beuschlein; Martin Reincke Journal: Eur J Endocrinol Date: 2014-08 Impact factor: 6.664
Authors: Thang S Han; Elon Correa; Michael E J Lean; David M Lee; Terrence W O'Neill; György Bartfai; Gianni Forti; Aleksander Giwercman; Krzysztof Kula; Neil Pendleton; Margus Punab; Martin K Rutter; Dirk Vanderschueren; Ilpo T Huhtaniemi; Frederick C W Wu; Felipe F Casanueva Journal: Endocrine Date: 2016-10-13 Impact factor: 3.633
Authors: M A Minetto; C Caresio; M Salvi; V D'Angelo; N E Gorji; F Molinari; G Arnaldi; S Kesari; E Arvat Journal: J Endocrinol Invest Date: 2018-11-15 Impact factor: 4.256
Authors: Frederick Vogel; Leah T Braun; German Rubinstein; Stephanie Zopp; Heike Künzel; Finn Strasding; Adriana Albani; Anna Riester; Ralf Schmidmaier; Martin Bidlingmaier; Marcus Quinkler; Timo Deutschbein; Felix Beuschlein; Martin Reincke Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958